GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » EBIT

OncoSil Medical (ASX:OSL) EBIT : A$-12.89 Mil (TTM As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is OncoSil Medical EBIT?

OncoSil Medical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was A$-7.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-12.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OncoSil Medical's annualized ROC % for the quarter that ended in Dec. 2024 was -3,540.61%. OncoSil Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -5,343.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. OncoSil Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -128.47%.


OncoSil Medical EBIT Historical Data

The historical data trend for OncoSil Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSil Medical EBIT Chart

OncoSil Medical Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.26 -10.43 -11.54 -11.34 -12.38

OncoSil Medical Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.65 -5.69 -6.70 -5.67 -7.21

Competitive Comparison of OncoSil Medical's EBIT

For the Medical Devices subindustry, OncoSil Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSil Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OncoSil Medical's EV-to-EBIT falls into.



OncoSil Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-12.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSil Medical  (ASX:OSL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OncoSil Medical's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-14.428 * ( 1 - 0% )/( (0.244 + 0.571)/ 2 )
=-14.428/0.4075
=-3,540.61 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

OncoSil Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.428/( ( (0.113 + max(-1.188, 0)) + (0.427 + max(-0.263, 0)) )/ 2 )
=-14.428/( ( 0.113 + 0.427 )/ 2 )
=-14.428/0.27
=-5,343.70 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.117 + 0 + 0.392) - (1.614 + 0 + 0.083)
=-1.188

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.014 + 0 + 0.593) - (2.759 + 0 + 0.111)
=-0.263

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

OncoSil Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-12.887/10.031
=-128.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSil Medical EBIT Related Terms

Thank you for viewing the detailed overview of OncoSil Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSil Medical Business Description

Traded in Other Exchanges
N/A
Address
7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.

OncoSil Medical Headlines

No Headlines